The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis

Rheumatology (United Kingdom)

Volumn 58, Issue 2, 2019, Pages 197-205

  Veale, Douglas J ^a,b   McGonagle, Dennis ^c,d   McInnes, Iain B ^e   Krueger, James G ^f   Ritchlin, Christopher T ^g   Elewaut, Dirk ^h,i   Kanik, Keith S ^j   Hendrikx, Thijs ^j   Berstein, Gabriel ^j   Hodge, Jennifer ^j   Telliez, Jean Baptiste ^j  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f ROCKEFELLER UNIVERSITY   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^h GHENT UNIVERSITY   (Belgium)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j PFIZER INC   (United States)

more..

Author keywords

Bone; Cytokines and inflammatory mediators; DMARDs; Gastrointestinal; Ligaments and tendons; Skin; Spondyloarthropathies (including psoriatic arthritis); Synovium

Indexed keywords

BARICITINIB; CYTOKINE; FILGOTINIB; JANUS KINASE; JANUS KINASE INHIBITOR; PEFICITINIB; TOFACITINIB; UPADACITINIB; ANTIRHEUMATIC AGENT; STAT PROTEIN;

DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; JAK-STAT SIGNALING; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SPONDYLARTHRITIS; IMMUNOLOGY; PSORIATIC ARTHRITIS; SIGNAL TRANSDUCTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CYTOKINES; HUMANS; JANUS KINASE INHIBITORS; JANUS KINASES; SIGNAL TRANSDUCTION; SPONDYLARTHRITIS; STAT TRANSCRIPTION FACTORS;

EID: 85055105305     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key070     Document Type: Review

References (72)

1. van der Horst-Bruinsma IE, Nurmohamed MT. Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis 2012;4:413-22.
2. Coates LC, Kavanaugh A, Mease PJ et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016;68:1060-71.
3. Orr C, Veale DJ. Is there a need for new agents with novel mechanisms of action in psoriatic arthritis? Ann Rheum Dis 2014;73:951-3.
4. Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med 2016;67:337-53.
5. McGonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H. 'MHC-I-opathy'-unified concept for spondyloarthritis and Behcet disease. Nat Rev Rheumatol 2015;11:731-40.
6. Ghoreschi K, Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol 2014;23:7-11.
7. Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 2017;18:374-84.
8. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72 (Suppl 2):ii111-5.
9. Benjamin M, McGonagle D. Histopathologic changes at "synovio-entheseal complexes" suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. Arthritis Rheum 2007;56:3601-9.
10. Baeten D, Breban M, Lories R, Schett G, Sieper J. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 2013;65:12-20.
11. Ellinghaus D, Jostins L, Spain SL et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 2016;48:510-8.
12. Arakawa A, Siewert K, Stöhr J et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 2015;212:2203-12.
13. Menon B, Gullick NJ, Walter GJ et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014;66:1272-81.
14. Sherlock JP, Joyce-Shaikh B, Turner SP et al. IL-23 induces spondyloarthropathy by acting on ROR-gt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012;18:1069-76.
15. Jacques P, Lambrecht S, Verheugen E et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis 2014;73:437-45.
16. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
17. Costello ME, Ciccia F, Willner D et al. Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol 2015;67:686-91.
18. Tito RY, Cypers H, Joossens M et al. Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol 2017;69:114-21.
19. Van de Wiele T, Van Praet JT, Marzorati M, Drennan MB, Elewaut D. How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol 2016;12:398-411.
20. Scher JU, Littman DR, Abramson SB. Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol 2016;68:35-45.
21. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-87.
22. Spits H, Bernink JH, Lanier L. NK cells and type 1 innate lymphoid cells: partners in host defense. Nat Immunol 2016;17:758-64.
23. Langrish CL, McKenzie BS, Wilson NJ et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004;202:96-105.
24. Smith JA, Colbert RA. The IL-23/IL-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol 2014;66:231-41.
25. Sieper J, Braun J, Kay J et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 2015;74:1051-7.
26. Krueger J, Clark JD, Suárez-Farinãs M et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol 2016;137:1079-90.
27. Gao W, McGarry T, Orr C et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Ann Rheum Dis 2016;75:311-5.
28. Paine A, Ritchlin C. Bone remodeling in psoriasis and psoriatic arthritis: an update. Curr Opin Rheumatol 2016;28:66-75.
29. Braem K, Lories RJ. Insights into the pathophysiology of ankylosing spondylitis: contributions from animal models. Joint Bone Spine 2012;79:243-8.
30. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099-112.
31. Milia AF, Ibba-Manneschi L, Manetti M et al. Evidence for the prevention of enthesitis in HLA-B27/hβ(2)m transgenic rats treated with a monoclonal antibody against TNF-α. J Cell Mol Med 2011;15:270-9.
32. van Tok M, van Duivenvoorde LM, Kramer I et al. Anti-IL- 17A treatment blocks inflammation, destruction and new bone formation in experimental spondyloarthritis in HLA-B27 transgenic rats. Arthritis Rheumatol 2015;67 (suppl 10). http://acrabstracts.org/abstract/anti-il-17atreatment- blocks-inflammation-destruction-and-newbone- formation-in-experimental-spondyloarthritis-in-hlab27- transgenic-rats/ (20 March 2018, date last accessed).
33. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-98.
34. Ruutu M, Thomas G, Steck R et al. β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. Arthritis Rheum 2012;64:2211-22.
35. Reinhardt A, Yevsa T, Worbs T et al. Interleukin- 23-dependent g/d T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol 2016;68:2476-86.
36. De Wilde K, Martens A, Lambrecht S et al. A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis. Ann Rheum Dis 2017;76:585-92.
37. Yokota K, Sato K, Miyazaki T et al. Combination of tumor necrosis factor a and interleukin-6 induces mouse osteoclast- like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol 2014;66:121-9.
38. Mikami Y, Asano M, Honda MJ, Takagi M. Bone morphogenetic protein 2 and dexamethasone synergistically increase alkaline phosphatase levels through JAK/STAT signaling in C3H10T1/2 cells. J Cell Physiol 2010;223:123-33.
39. Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41.
40. Dowty ME, Lin J, Ryder TF et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans. Drug Metab Dispos 2014;42:759-73.
41. Hodge JA, Kawabata TT, Krishnaswami S et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016;34:318-28.
42. Mease P, Hall S, Fitzgerald O et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 2017;377:1537-50.
43. Gladman D, Rigby W, Azevedo VF et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 2017;377:1525-36.
44. van der Heijde D, Deodhar A, Wei JC et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 2017;76:1340-7.
45. Asquith M, Elewaut D, Lin P, Rosenbaum JT. The role of the gut and microbes in the pathogenesis of spondyloarthritis. Best Pract Res Clin Rheumatol 2014;28:687-702.
46. Danese S, Grisham MB, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016;310:G155-62.
47. Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723-36.
48. Panés J, Sandborn WJ, Schreiber S et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut 2017;66:1049-59.
49. Vermeire S, Schreiber S, Petryka R et al. Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's disease: interim analysis from the Phase 2 FITZROY study. J Crohns Colitis 2016;10:S15.
50. Marks DJ. Defective innate immunity in inflammatory bowel disease: a Crohn's disease exclusivity? Curr Opin Gastroenterol 2011;27:328-34.
51. Bachelez H, van de Kerkof PC, Strohal R et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised noninferiority trial. Lancet 2015;386:552-61.
52. Bissonnette R, Iversen L, Sofen H et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol 2015;172:1395-406.
53. Papp KA, Menter A, Abe M et al. Two Phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results. J Am Acad Dermatol 2015;72 (Suppl 1):AB66.
54. Ports WC, Khan S, Lan S et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013;169:137-45.
55. Bissonnette R, Papp KA, Poulin Y et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016;175:902-11.
56. Papp KA, Menter MA, Raman M et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 2016;174:1266-76.
57. Liew SH, Nichols KK, Klamerus KJ et al. Tofacitinib (CP-690, 550), a Janus kinase inhibitor for dry eye disease: results from a Phase 1/2 trial. Ophthalmology 2012;119:1328-35.
58. Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology 2014;121:365-76.
59. Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
60. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
61. Kremer J, Li Z-G, Hall S et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253-61.
62. Lee EB, Fleischmann R, Hall S et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
63. van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
64. van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
65. Wollenhaupt J, Silverfield J, Lee EB et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837-52.
66. Genovese MC, Kremer J, Zamani O et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243-52.
67. Kremer JM, Emery P, Camp HS et al. A Phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to antitumor necrosis factor therapy. Arthritis Rheumatol 2016;68:2867-77.
68. Namour F, Diderichsen PM, Cox E et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of Phase IIb dose selection. Clin Pharmacokinet 2015;54:859-74.
69. Kivitz AJ, Gutierrez-Urenã SR, Poiley J et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol 2017;69:709-19.
70. Ghoreschi K, Jesson MI, Li X et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J Immunol 2011;186:4234-43.
71. Dowty M, Lin T, Wang L et al. Lack of differentiation of Janus kinase inhibitors in rheumatoid arthritis based on Janus kinase pharmacology and clinically meaningful concentrations. Ann Rheum Dis 2014;73 (Suppl 2):116.
72. Wollenhaupt J, Silverfield J, Lee EB et al. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and clinical and radiographic efficacy in open-label, long-term extension studies over 7 years. Arthritis Rheumatol 2015;67:1645 (abstract).